XML 137 R80.htm IDEA: XBRL DOCUMENT v3.22.4
Contract revenues, Anti-Tau Antibody in AD - 2012 Agreement with Genentech (Details)
SFr in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 36 Months Ended 127 Months Ended
Jul. 31, 2016
CHF (SFr)
Dec. 31, 2017
CHF (SFr)
Jun. 30, 2016
CHF (SFr)
Dec. 31, 2022
CHF (SFr)
Dec. 31, 2021
CHF (SFr)
Dec. 31, 2020
CHF (SFr)
Dec. 31, 2015
CHF (SFr)
Dec. 31, 2022
CHF (SFr)
Dec. 31, 2022
CHF (SFr)
payment
Jun. 30, 2012
CHF (SFr)
Contract revenues                    
Revenue from contracts with customers       SFr 3,935 SFr 0 SFr 15,431        
Anti-tau Antibody in AD [Member] | 2012 Agreement with Genentech [Member]                    
Contract revenues                    
Period to provide notice of termination of agreement       3 months            
Cumulative payments received       SFr 59,000       SFr 59,000 SFr 59,000  
Milestone payment received SFr 14,000 SFr 14,000         SFr 14,000   SFr 42,000  
Up-front consideration received                   SFr 17,000
Number of milestone payments received | payment                 3  
Revenue from contracts with customers   SFr 14,000 SFr 14,000         0    
Collaborative agreement, Notice of contract termination period in case of material breach of contract       90 days            
Anti-tau Antibody in AD [Member] | 2012 Agreement with Genentech [Member] | Minimum                    
Contract revenues                    
Total potential collaboration agreement value                   SFr 400,000
Anti-tau Antibody in AD [Member] | 2012 Agreement with Genentech [Member] | Maximum                    
Contract revenues                    
Total potential collaboration agreement value remaining       SFr 368,500       SFr 368,500 SFr 368,500